

FIG. 1

SUMMARY OF STX2 Hu mAb ACTIVITY  
AGAINST CLINICAL STX2 AND STX2 VARIANTS





FIG.2

FIG.3



AVERAGE SURVIVAL OF MICE GIVEN 5, 10, 20, 35, OR 50  $\mu$ g OF Stx2-SPECIFIC Hu-mAbs FOLLOWED 18 HOURS LATER WITH 25ng Stx2





FIG. 4

IN VITRO NEUTRALIZATION OF Stx2 AND Stx2c  
(PRODUCED BY CLINICAL STEC ISOLATES)  
BY Stx2-SPECIFIC Hu-mAb




SHIGA TOXIN PRODUCING *E. coli* ISOLATES

5H8 = anti-A+B subunit  
6G3 = anti-A+B subunit  
2F10 = anti-A subunit  
3E9 = anti-A subunit  
5C12 = anti-A subunit

FIG.5

# FIG.6

Stx2c PRODUCING *E. coli* ISOLATE (95-8061)



AVERAGE DAYS OF SURVIVAL OF MICE GIVEN 30 µg  
Hu-mAb 2F10, 3E9, 5C12, 5H8, OR 6G3 FOLLOWED 18 HOURS LATER  
WITH Stx2c CONTAINING CULTURE SUPERNATANT